Alkermes ALKS Medicaid Rebate — Accrued Sales Discounts Allowances And Reserves

Similar metrics at other companies

JAK

JAKKSales Reserves Allowances

$26.74M+1.9%

UEICAccrued Sales Discounts Rebates And Royalties, Current

$4.16M—

UEICAccrued Sales Discounts Rebates And Royalties, Current

$4.16M—

KNXEmployee medical reserves — Accrued Insurance

$33.5M+34.7%

CRMDVolume Incentive Rebates — Accrued reserves and allowances to accounts receivable

$98.2M+253%

MRKSales Rebates and Discounts

$1.5B-31.8%

FAQ

What is Alkermes's medicaid rebate — accrued sales discounts allowances and reserves?

Alkermes (ALKS) reported medicaid rebate — accrued sales discounts allowances and reserves of $192.62M in Q2 2026.

How has Alkermes's medicaid rebate — accrued sales discounts allowances and reserves changed year-over-year?

Alkermes's medicaid rebate — accrued sales discounts allowances and reserves increased by 1.9% year-over-year, from $189.02M to $192.62M.

What is the long-term trend for Alkermes's medicaid rebate — accrued sales discounts allowances and reserves?

Over 3 years (2022 to 2025), Alkermes's medicaid rebate — accrued sales discounts allowances and reserves has grown at a -2.3% compound annual growth rate (CAGR), from $813.84M to $757.99M.

What does medicaid rebate — accrued sales discounts allowances and reserves mean?

This metric represents the estimated financial liability accrued for rebates owed to state Medicaid programs based on the sales of specific pharmaceutical products. It reflects the company's obligation to provide price concessions to government payers as mandated by regulatory requirements for drug reimbursement. These accruals are critical for accurately reporting net revenue by accounting for the difference between gross sales and the expected net realization after government-mandated discounts.